Cargando…

APOC-III: a Gatekeeper in Controlling Triglyceride Metabolism

PURPOSE OF REVIEW: Apolipoprotein C-III (ApoC-III) is a widely known player in triglyceride metabolism, and it has been recently recognized as a polyhedric factor which may regulate several pathways beyond lipid metabolism by influencing cardiovascular, metabolic, and neurological disease risk. This...

Descripción completa

Detalles Bibliográficos
Autores principales:	Giammanco, Antonina, Spina, Rossella, Cefalù, Angelo B., Averna, Maurizio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9947064/ https://www.ncbi.nlm.nih.gov/pubmed/36689070 http://dx.doi.org/10.1007/s11883-023-01080-8

Ejemplares similares

DeepSRE: Identification of sterol responsive elements and nuclear transcription factors Y proximity in human DNA by Convolutional Neural Network analysis
por: Noto, Davide, et al.
Publicado: (2021)

The Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans
por: Borén, Jan, et al.
Publicado: (2020)

The pathophysiology of intestinal lipoprotein production
por: Giammanco, Antonina, et al.
Publicado: (2015)

APOC3: Triglycerides do matter
por: Hassan, Mohamed
Publicado: (2014)

Interventional hepatic apoC-III knockdown improves atherosclerotic plaque stability and remodeling by triglyceride lowering
por: Ramms, Bastian, et al.
Publicado: (2022)

Metabolic characterisation of disturbances in the APOC3/triglyceride-rich lipoprotein pathway through sample-based recall by genotype
por: Corbin, Laura J., et al.
Publicado: (2020)

ApoC-III and visceral adipose tissue contribute to paradoxically normal triglyceride levels in insulin-resistant African-American women
por: Sumner, Anne E, et al.
Publicado: (2013)

A rare variant in APOC3 is associated with plasma triglyceride and VLDL levels in Europeans
por: Timpson, Nicholas J., et al.
Publicado: (2014)

Dissociation Between APOC3 Variants, Hepatic Triglyceride Content and Insulin Resistance
por: Kozlitina, Julia, et al.
Publicado: (2011)

Lipoprotein Abnormalities in Chronic Kidney Disease and Renal Transplantation
por: Barbagallo, Carlo Maria, et al.
Publicado: (2021)

Hyperalphalipoproteinemia and Beyond: The Role of HDL in Cardiovascular Diseases
por: Giammanco, Antonina, et al.
Publicado: (2021)

Erratum: A rare variant in APOC3 is associated with plasma triglyceride and VLDL levels in Europeans
por: Timpson, Nicholas J., et al.
Publicado: (2015)

Frequency and phenotype consequence of APOC3 rare variants in patients with very low triglyceride levels
por: Crawford, Dana C., et al.
Publicado: (2018)

ApoC-III is a novel inducer of calcification in human aortic valves
por: Schlotter, Florian, et al.
Publicado: (2021)

Sex differences in HDL ApoC-III in American Indian youth
por: Blackett, Piers R, et al.
Publicado: (2012)

APOC3 rs2070667 Associates with Serum Triglyceride Profile and Hepatic Inflammation in Nonalcoholic Fatty Liver Disease
por: Xu, Qing-Yang, et al.
Publicado: (2020)

N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels
por: Alexander, Veronica J, et al.
Publicado: (2019)

Ethnic differences in ApoC-III concentration and the risk of cardiovascular disease: No evidence for the cardioprotective role of rare/loss of function APOC3 variants in non-Europeans
por: Rout, Madhusmita, et al.
Publicado: (2022)

Lack of Correlation of Plasma HDL With Fecal Cholesterol and Plasma Cholesterol Efflux Capacity Suggests Importance of HDL Functionality in Attenuation of Atherosclerosis
por: Srivastava, Neelam, et al.
Publicado: (2018)

The gatekeeper of Yersinia type III secretion is under RNA thermometer control
por: Pienkoß, Stephan, et al.
Publicado: (2021)

Short hydrocarbon stapled ApoC2-mimetic peptides activate lipoprotein lipase and lower plasma triglycerides in mice
por: Sviridov, Denis, et al.
Publicado: (2023)

40 Years of the APOC Partnership
por: Roungou, Jean-Baptist, et al.
Publicado: (2015)

Statin-induced autoimmune myositis: a proposal of an “experience-based” diagnostic algorithm from the analysis of 69 patients
por: Gagliardo, Carola Maria, et al.
Publicado: (2023)

Role of Nutraceuticals in Hypolipidemic Therapy
por: Barbagallo, Carlo M., et al.
Publicado: (2015)

New Therapeutic Approaches to the Treatment of Dyslipidemia 1: ApoC-III and ANGPTL3
por: Kim, Ji Yoon, et al.
Publicado: (2023)

APOC3 genetic variation, serum triglycerides, and risk of coronary artery disease in Asian Indians, Europeans, and other ethnic groups
por: Goyal, Shiwali, et al.
Publicado: (2021)

Associations of the APOC3 rs5128 polymorphism with plasma APOC3 and lipid levels: a meta-analysis
por: Song, Yongyan, et al.
Publicado: (2015)

Enhanced Lipid Peroxidation and Platelet Activation as Potential Contributors to Increased Cardiovascular Risk in the Low‐HDL Phenotype
por: Vazzana, Natale, et al.
Publicado: (2013)

Postprandial metabolism of apolipoproteins B48, B100, C-III, and E in humans with APOC3 loss-of-function mutations
por: Taskinen, Marja-Riitta, et al.
Publicado: (2022)

Emerging Evidence that ApoC-III Inhibitors Provide Novel Options to Reduce the Residual CVD
por: Taskinen, Marja-Riitta, et al.
Publicado: (2019)

Investing in Onchocerciasis Control: Financial Management of the African Programme for Onchocerciasis Control (APOC)
por: Bundy, Donald A. P., et al.
Publicado: (2015)

Effects of PCSK9 inhibitors on HDL cholesterol efflux and serum cholesterol loading capacity in familial hypercholesterolemia subjects: a multi-lipid-center real-world evaluation
por: Palumbo, Marcella, et al.
Publicado: (2022)

BopN is a Gatekeeper of the Bordetella Type III Secretion System
por: Navarrete, Kevin Munoz, et al.
Publicado: (2023)

Very-Low-Density Lipoprotein–Associated Apolipoproteins Predict Cardiovascular Events and Are Lowered by Inhibition of APOC-III
por: Pechlaner, Raimund, et al.
Publicado: (2017)

APOC3 Interference for Familial Chylomicronaemia Syndrome
por: Hegele, Robert A
Publicado: (2022)

ApoC-III ASO promotes tissue LPL activity in the absence of apoE-mediated TRL clearance
por: Ramms, Bastian, et al.
Publicado: (2019)

An APOC3 3′UTR variant associated with plasma triglycerides levels and coronary heart disease by creating a functional miR-4271 binding site
por: Hu, Sen-Lin, et al.
Publicado: (2016)

Managing the Fight against Onchocerciasis in Africa: APOC Experience
por: Fobi, Grace, et al.
Publicado: (2015)

AAV-Mediated ApoC2 Gene Therapy: Reversal of Severe Hypertriglyceridemia and Rescue of Neonatal Death in ApoC2-Deficient Hamsters
por: Yang, Chun, et al.
Publicado: (2020)

Gatekeepers of Knowledge
por: Zeegers, Margaret
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_vp0nc87c0enf8ho4q2t77d5vnu